Statin Therapy in Ischemia-Reperfusion Injury during coronary artery bypass grafting.
Statin therapy in Ischemia-Reperfusion Injury: A randomised trial to evaluate the effect of high dose rosuvastatin on myocardial infarct size post coronary artery bypass grafting (CABG).
South Australian Health and Medical Research Institute
100 participants
Feb 4, 2013
Interventional
Conditions
Summary
The primary purpose of the study is to ascertain whether giving high doses of a cholesterol lowering drug (statin) can reduce the amount of damage caused to the heart by having a lack of oxygen and then having blood restored to the heart quickly when the bypass surgery is done. Tissue damage may be caused when the supply of oxygen is restored to the heart. There are sound biological reasons but limited data that shows that by giving a high dose of a statin drug it is believed that the injury to the heart may be lessened.
Eligibility
Inclusion Criteria2
- Adult patients who are scheduled to undergo elective on-pump CABG with or without aortic valve replacement.
- For patients on statins pre-CABG, statin dose must be unchanged for 30 days pre-CABG.
Exclusion Criteria10
- Standard CMR contra-indications
- Known intolerance to statins
- Renal (eGFR <45mls/min) and hepatic impairment
- Emergency CABG
- Mitral or tricuspid valve repair or replacement
- Off-pump CABG
- Patients who are Filipino, Chinese, Japanese, Korean or Vietnamese
- Patients on cyclosporine, gemfibrozil or fisidic acid
- Patients who are already on rosuvastatin or atorvastatin 80 mgs pre-CABG
- Re-do surgery
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rosuvastatin 40mgs orally at 36 hours and 12 hours pre CABG and then rosuvastatin 40 mgs daily for 7 days post CABG.
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000031763